Novo Nordisk shares tank 20% after latest obesity drug disappoints
Next-generation drug falls shortOver £70 billion wiped off market valueRace is on for launch of oral drugDanish diabetes and obesity drug specialist Novo Nordisk (NOVO-B:CPH) gave investors a nasty surprise on Friday (20 Dec)...
20 December 2024